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atients on maintenance hemodialysis (HD) require a
reliable vascular access; however, only half of
newly created radiocephalic arteriovenous fistulas
(RCAVF) can be used for HD without additional pro-
cedures to promote maturation and up 25% fail to
provide adequate vascular access for HD.1 The need for
subsequent creation of upper arm arteriovenous fistulas
(AVFs) and arteriovenous grafts may decrease if
maturation can be improved. Currently, no pharma-
cological treatments have been proven to improve
clinical maturation of AVFs.
Although the underlying pathophysiology of non-
maturation is incompletely understood, impaired out-
ward remodeling and neointimal hyperplasia in the
venous outflow tract seem to contribute.2 Studies in
murine and porcine models of AVF failure revealed a
pronounced inflammatory response in the venous
outflow tract in the early phase after AVF surgery.3
Recent studies suggest that this inflammatory
response impairs AVF maturation.4International Reports (2020) -, -–-Pegylated liposomes have emerged as an attractive
tool to facilitate selective delivery of drugs to inflamed
tissues with a highly permeable microvasculature,
where liposomes are being phagocytized by macro-
phages. It has a potent and long-lasting anti-inflam-
matory effect at sites of inflammation, while
minimizing exposure of noninflamed tissues. In a mu-
rine model of AVF failure, we have demonstrated that
liposomal prednisolone inhibits inflammation of the
juxta-anastomotic vein and improves outward remod-
eling of the venous outflow tract.5
We hypothesized that maturation of RCAVFs in
humans can be improved by inhibition of juxta-
anastomotic inflammation using liposomal predniso-
lone. In the Liposomal Prednisolone to Improve
Hemodialysis Fistula Maturation (LIPMAT) study,
we aimed to assess if liposomal prednisolone
improves maturation of RCAVFs and if it can be
safely administered to patients with end-stage renal
disease. The design of this multicenter randomized1
Figure 1. Study flow chart.
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From April 2016 through May 2018, 109 patients
were planned for RCAVF creation and assessed for
study eligibility. A total of 64 patients were
excluded for known exclusion criteria from their
medical history (n ¼ 24), not consenting to study
participation (n ¼ 34), or late referral (n ¼ 6,
2
Figure 1). Of the remaining 45 patients who provided
informed consent, 32 were randomized (Table 1).
Reasons for dropout are shown in Figure 1. After
randomization, but before treatment, 2 patients
experienced clinical events constituting exclusion
criteria. The remaining 30 patients received the study
treatment. The trial was stopped prematurely in May
2018 because of slow enrollment.
End Points
The primary end point was assessed in 29 patients. The
distal cephalic diameter was 3.9 mm (95% confidenceKidney International Reports (2020) -, -–-









Age, yr 70  8.5 65  12 67  11
Gender
Female 5 (38) 1 (6) 6 (21)
Male 8 (62) 15 (94) 23 (79)
Race
Caucasian 11 (85) 13 (81) 24 (83)
Hindustani Surinamese 1 (8) 2 (13) 3 (10)
Moroccan 0 (0) 1 (6) 1 (3)
Asian 1 (8) 0 (0) 1 (3)
Cause of renal failure
Diabetes mellitus 4 (31) 6 (38) 10 (35)
Renal vascular disease 5 (39) 4 (25) 9 (31)
Glomerulonephritis 3 (23) 2 (13) 5 (17)
Interstitial nephropathy 1 (8) 2 (13) 3 (10)
Cystic kidney disease 0 (0) 2 (13) 2 (7)
Comorbidities
Diabetes mellitus 7 (54) 7 (44) 14 (48)
Coronary artery disease 6 (46) 4 (25) 10 (35)
Peripheral artery disease 4 (31) 3 (19) 7 (24)
Cerebrovascular disease 5 (39) 4 (25) 9 (31)
Medication
ACE inhibitor 1 (8) 6 (38) 7 (24)
Angiotensin 2 receptor blocker 8 (62) 5 (31) 13 (45)
Loop diuretic 8 (62) 9 (56) 17 (59)
Aldosterone receptor antagonist 0 (0) 1 (6) 1 (3)
Beta blocker 10 (77) 8 (50) 18 (62)
Calcium channel blocker 8 (62) 11 (69) 19 (66)
Platelet inhibitor 4 (31) 10 (63) 14 (48)
Anticoagulant 2 (15) 3 (19) 5 (17)
Vitamin D 12 (92) 13 (81) 25 (86)
ACE, angiotensin-converting enzyme; LIPMAT, Liposomal Prednisolone to Improve
Hemodialysis Fistula Maturation.
Data are reported as mean  SD or n (%).
Table 2. Effect of liposomal prednisolone on primary and secondary













3.9 (2.7–5.8) 3.7 (3.0–5.3) 0.88
Elbow diameter, mm 5.5 (4.7–6.7) 5.0 (4.0–6.1) 0.47
Mid upper arm
diameter, mm




3.6 (2.9–4.2) 3.6 (3.0–4.0) 0.83
Flow, ml/min 456 (277–688) 406 (300–772) 0.81
Brachial artery





4.2 (2.3–6.1) 4.9 (3.9–5.8) 0.43
Elbow diameter, mm 6.2 (4.7–6.9) 5.7 (4.4–6.3) 0.35
Mid upper arm
diameter, mm




4.0 (2.1–5.0) 3.6 (3.0–4.6) 1.00
Flow, ml/min 546 (110–1037) 560 (334–970) 0.65
Brachial artery
Flow, ml/min 800 (434–1485) 798 (479–1019) 0.60
IQR, inter quartile range; LIPMAT, Liposomal Prednisolone to Improve Hemodialysis
Fistula Maturation.
RESEARCH LETTERinterval, 2.7–5.8 mm) in the placebo group and 3.7 mm
(95% confidence interval, 3.0–5.3 mm) in the treatment
group (P ¼ 0.88). No significant results were observed
for secondary end points (Table 2).Functional Outcomes
At the time of assessment of the functional outcomes,
54% of AVFs in the placebo arm and 69% in the
liposomal prednisolone arm were successfully used
for HD (P ¼ 0.41). Seven patients (44%) in the
liposomal prednisolone arm and 4 patients (31%) in
the placebo group underwent an endovascular or
surgical procedure to achieve RCAVF maturation.
During follow-up, in the placebo and liposomal
prednisolone groups, respectively 23% and 13% of
RCAVFs had failed (P ¼ 0.45). The functional
outcome could not be determined for 6 patients,
because of loss to follow-up (2 patients who moved
abroad) or not initiating HD (Table 3).Kidney International Reports (2020) -, -–-Safety
No infusion reactions were observed except for 1 subject
in the liposomal prednisolone arm who was known to
have symptoms of orthostatic hypotension, and experi-
enced mild dizziness without hypotension on postural
change during the infusion. The incidence of symptoms
related to progressive renal failure and cardiovascular
events was similar in both treatment arms (Table 4).
Infections
In the liposomal prednisolone arm, 5 infections were
observed in the 3 months of follow-up. One subject was
treated with antibiotics due to erythema in the AVF
arm, without fever or systemic symptoms. One subject
experienced 2 episodes of mild rhinosinusitis that
resolved without specific treatment. One subject died
72 days after AVF surgery, because of progressive fluid
overload, complicated by septicemia from a possible
catheter-related infection or pneumonia. In the placebo
group, 1 subject experienced a dental abscess 3 months
after AVF surgery.
DISCUSSION
In the LIPMAT study, we evaluated if liposomal
prednisolone improves maturation of RCAVFs. The trial3
Table 3. Effect of liposomal prednisolone on functional outcomes of







Without procedures to improve maturation 3 (23) 4 (25)
With procedures to improve maturation 4 (31) 7 (44)
AVF not used
Failed due to nonmaturation 3 (23) 2 (13)
Kidney transplantation 0 (0) 1 (6)
Did not reach ESRD 1 (8) 1 (6)
Deceased before ESRD 0 (0) 1 (6)
Loss to follow-up 2 (16) 0 (0)
Values are n (%).
AVF, arteriovenous fistula; ESRD, end-stage renal disease; LIPMAT, Liposomal Pred-
nisolone to Improve Hemodialysis Fistula Maturation.








Revision surgery 1 0
Coiling or ligation of collateral veins 1 2
Hematoma or bleeding 2 1
New AVF within 3 months 1 1
Nerve damage 1 0
Edema 1 0
Infusion-related events
Orthostatic symptoms (no hypotension) 0 1
Renal and metabolic
Fluid overload 3 2
Gout 1 0
Uremia (worsening) 1 0
Anemia (worsening) 1 1
Cardiovascular
Atrial fibrillation/flutter 2 4
Myocardial infarction 1 2
Angina pectoris (worsening) 0 1
Intermittent claudication (worsening) 1 0
Infectious
AVF site infection 0 1
Cellulitis (non-AVF site) 0 1




Accidental injury 3 2
Fatigue and sleep disorders 4 4
Liver enzyme abnormalities 2 2
Hyperthyroidism 0 1
Hair loss 1 0
Intoxication 0 1




Gastric pain 0 1
Hematoma non-AVF site 0 1
Urinary catheter placement 0 1
Myocardial infarction includes non-ST-elevation myocardial infarction.
AVF, arteriovenous fistula; LIPMAT, Liposomal Prednisolone to Improve Hemodialysis
Fistula Maturation.
RESEARCH LETTERwas terminated because of slow enrollment after in-
clusion of 30 of the 80 subjects initially aimed for. We
present the study to investigate feasibility and to
report preliminary outcomes. Liposomal prednisolone
was safe and well-tolerated by patients with end-stage
renal disease. No severe infusion reactions were
observed and no severe infections were observed
within the expected duration of effect of liposomal
prednisolone. Liposomal prednisolone did not result in
improved RCAVF maturation as measured by ultra-
sound at 6 weeks and 3 months after surgery. The 62%
successful cannulation rate observed in the LIPMAT
study was comparable to previous studies on func-
tional AVF maturation.1,7 Although the nonsignificant
result may be a mere result of a lack of power due to
the small sample size, also no trend toward any dif-
ference between the treatment and control group was
observed. Apart from a lack of statistical power, several
factors might explain the lack of therapeutic efficacy of
liposomal prednisolone to improve AVF maturation.
First, the local concentration of liposomal prednisolone
in the vessel wall of the AVF might not have been
sufficient to exert a strong anti-inflammatory effect.
The local accumulation of liposomal prednisolone could
not be examined, as the AVFs could not be sacrificed
for examination. In addition, no approved formulation
of the compound was available to trace the liposomes
in vivo in humans. Second, the inflammatory response
in the RCAVF might have been too limited to induce
significant local vascular accumulation of the lipo-
somes. Previous clinical studies revealed substantial
localization of liposomal prednisolone in the athero-
sclerotic arterial wall.8 As the prevalence of athero-
sclerosis was high in the LIPMAT subjects (Table 1), a
significant proportion of liposomal prednisolone may
therefore have accumulated in nontarget vessel walls
instead of the AVF vein. In future studies, tissue
samples of AVFs that failed early may be acquired4
during surgical revisions and analyzed for liposomal
prednisolone content.
The extent and timing of venous inflammation after
AVF surgery in humans is not fully known. To avoid
potential detrimental effects on wound healing, lipo-
somal prednisolone was not administered before sur-
gery. As most of outward remodeling of AVFs has been
shown to occur within the first 4 weeks after surgery,9
we aimed to cover this interval by administering the
drug at day 1 and 15 after surgery. This might have
been too short, with significant inflammation persisting
at 4 weeks after surgery.Kidney International Reports (2020) -, -–-
RESEARCH LETTERCONCLUSION AND FURTHER DIRECTIONS
The LIPMAT study was the first to study an anti-
inflammatory strategy to improve AVF maturation in
humans. We could not demonstrate a clinically sig-
nificant impact on RCAVF maturation. Future studies
are needed to elucidate the role of inflammation in AVF
maturation and the clinical promise of liposomal for-
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